Powder: -20°C for 3 years | In solvent: -80°C for 1 year
McMMAF 是一种保护基团共轭的 MMAF。它是一种具有马来酰亚胺基己酰基接头(MC 接头)的 MMAF 衍生物, MMAF 是一种有效的微管蛋白聚合抑制剂。它可与抗体或其他蛋白质或生物聚合物结合。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 483 | 现货 | ||
5 mg | ¥ 1,120 | 现货 | ||
10 mg | ¥ 1,870 | 现货 | ||
25 mg | ¥ 3,180 | 现货 | ||
50 mg | ¥ 4,690 | 现货 | ||
100 mg | ¥ 6,680 | 现货 |
产品描述 | McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.It is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful agent for make antibody drug conjugate (ADC) for targeted drug delivery. |
体外活性 | MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). It cannot be used as a drug itself because MMAF is highly toxic. The linker to the monoclonal antibody is stable in extracellular fluid but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism. |
别名 | Maleimidocaproyl monomethylauristatin F |
分子量 | 925.16 |
分子式 | C49H76N6O11 |
CAS No. | 863971-19-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (108.09 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.0809 mL | 5.4045 mL | 10.8089 mL | 27.0224 mL |
5 mM | 0.2162 mL | 1.0809 mL | 2.1618 mL | 5.4045 mL | |
10 mM | 0.1081 mL | 0.5404 mL | 1.0809 mL | 2.7022 mL | |
20 mM | 0.054 mL | 0.2702 mL | 0.5404 mL | 1.3511 mL | |
50 mM | 0.0216 mL | 0.1081 mL | 0.2162 mL | 0.5404 mL | |
100 mM | 0.0108 mL | 0.054 mL | 0.1081 mL | 0.2702 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
McMMAF 863971-19-1 Cytoskeletal Signaling Microtubule Associated inhibit Maleimidocaproyl monomethylauristatin F Inhibitor Drug-Linker Conjugates for ADC inhibitor